Sam Chun Dang Pharm. Co., Ltd (KOSDAQ:000250)

Market Cap	21.09T +404.2%
Revenue (ttm)	220.74B +6.0%
Net Income	-11.40B
EPS	-490.31
Shares Out	23.26M
PE Ratio	n/a
Forward PE	n/a
Dividend	200.00 (0.03%)
Ex-Dividend Date	Dec 29, 2025

Volume	645,106
Average Volume	294,379
Open	805,000
Previous Close	795,000
Day's Range	776,000 - 955,000
52-Week Range	127,600 - 955,000
Beta	2.46
RSI	70.50
Earnings Date	Mar 25, 2026

About Sam Chun Dang Pharm.

Sam Chun Dang Pharm. Co., Ltd engages in the manufacturing and sale of pharmaceutical products in South Korea. It provides ethical and over the counter products in various therapeutic areas comprising ophthalmology, cardiovascular, endocrinology, antibacterial, anti-fungal, antiviral, respiratory, anti-inflammatory, antihistamine, and musculoskeletal products, as well as vitamins and gastro intestine products. The company is also involved in exporting activities. Sam Chun Dang Pharm. Co., Ltd was founded in 1943 and is headquartered in Seoul, S...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1943
• Employees: 422
• Stock Exchange: KOSDAQ
• Ticker Symbol: 000250

Financial Performance

In 2024, Sam Chun Dang Pharm.'s revenue was 210.92 billion, an increase of 9.47% compared to the previous year's 192.67 billion. Losses were -10.92 billion, 5.14% more than in 2023.